Huadong Medicine to Expand TCM Footprint with Acquisition of Hengba Pharmaceutical
Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced its intention to...
Beijing X-Magtech Secures Over RMB 100 Million in Series A+ Funding for Magnetic Field Measurement Tech
Beijing X-Magtech Technologies, a specialist in ultra-weak magnetic field measurement technology, has reportedly secured over...
BGI Genomics and Technopark Biogen Launch Astana Genetic Center to Boost Genetic Testing in Central Asia
Astana Genetic Center, a collaboration between China’s leading genomics company BGI Genomics Co., Ltd (SHE:...
Apeiron Therapeutics Sells Rights to CDK7 Inhibitor GTAEXS617 to Exscientia for USD 30 Million
Apeiron Therapeutics, a Shanghai-based biopharmaceutical company, has reached an agreement to sell all rights to...
WeDoctor Partners with Shanghai Children’s Medical Center to Enhance Pediatric Care
WeDoctor Holdings Ltd, a subsidiary of Chinese internet conglomerate Tencent Corporate Venture Capital (HKG: 0700)...
Bio-Thera Solutions Submits BLAs for Stelara Biosimilar BAT2206 to FDA and EMA
Bio-Thera Solutions Ltd, a biopharmaceutical company based in Guangzhou, has announced the submission of Biologic...
Novartis Delivers Strong Q2 2024 Results with 11% YoY Net Sales Increase
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has released its financial results for the second...
J&J Halts Development of Epilepsy Therapy ADX71149 After Phase II Trial Failure
Johnson & Johnson (J&J; NYSE: JNJ), a US-based multinational medical devices, pharmaceutical, and consumer packaged...
Abbott Laboratories Reports Q2 2024 Sales Growth of 9.3%, Led by Medical Devices and Diabetes Sales
Abbott Laboratories (NYSE: ABT), a global healthcare giant based in the US, has reported its...
Sino Biopharmaceutical Submits Market Approval Filing for CDK2/4/6 Inhibitor Culmerciclib in Breast Cancer
Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company in China, has announced the submission...
Eli Lilly’s Mounjaro Approved by China’s NMPA for Long-Term Weight Management
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company in the US, has announced...
China Issues Ethical Guidelines for Human Genome Editing, Prohibits Germline Editing
China’s Ministry of Science and Technology (MOST) has issued the Ethical Guidelines for Human Genome...
China’s NMPA Suspends Daewoong Bio’s Cefodizime Over Inspection Refusal
The National Medical Products Administration (NMPA) has issued a notice to suspend the import, sale,...
Bain Capital-Backed Tenacia Wins NMPA Approval for Ganaxolone Oral Suspension for CDKL5 Deficiency
Tenacia, a central nervous system (CNS) specialist company incubated by Bain Capital, has announced that...
MicroPort MedTech’s Vepack Filter Retriever Earns NMPA Marketing Approval
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a prominent medical device company based in...
Venus Medtech’s VenusP-Valve Receives Marketing Approval in Venezuela, Expanding Global Reach
Venus Medtech (Hangzhou) Inc., (HKG: 2500), a leading medical device company, has announced that it...
Anhui Anke Biotechnology Receives NMPA Clearance for Clinical Trial of mRNA Drug AFN0328 for HPV-Related Cancers
Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009), a biopharmaceutical company based in China, has...
Shanghai Sanyou Medical’s Cervical Thoracic Internal Fixation System Earns NMPA Approval
Shanghai Sanyou Medical Co., Ltd (SHA: 688085), a leading medical device company based in China,...
Suzhou New District Hi-tech Industrial Co., Ltd and Subsidiaries to Establish Biopharmaceutical FOF with SND Group
Suzhou New District Hi-tech Industrial Co., Ltd (SHA: 600736), a prominent company in China’s high-tech...
NeuShen Therapeutics and Livzon Pharma Strike Deal for Greater China Rights to NS-041
NeuShen Therapeutics, a Sino-US biopharmaceutical company, has entered into a licensing agreement with Livzon Pharmaceutical...